Aegis Capital Initiates Coverage On Accuray Incorporated(ARAY). The shares have been rated Buy. The rating by Aegis Capital was issued on Feb 6, 2017.
In a different note, On Dec 14, 2016, JP Morgan said it Downgrades its rating on Accuray Incorporated. In the research note, the firm Announces the price-target to $6 per share. The shares have been rated ‘Neutral’ by the firm.
Accuray Incorporated (ARAY) shares turned negative on Tuesdays trading session with the shares closing down -0.1 points or -1.72% at a volume of 3,69,344. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $5.75. The peak price level was also seen at $5.75 while the days lowest was $5.6. Finally the shares closed at $5.7. The 52-week high of the shares is $6.39 while the 52-week low is $4.45. According to the latest information available, the market cap of the company is $473 M.
Accuray Incorporated(ARAY) last announced its earnings results on Oct 27, 2016 for Fiscal Year 2017 and Q1.Company reported revenue of $86.51M. Analysts had an estimated revenue of $89.49M. Earnings per share were $-0.12. The reported EPS was above estimates by $0.02 or NaN%. Analysts had estimated an EPS of $-0.10.
Several Insider Transactions has been reported to the SEC. On Nov 9, 2015, Joshua Levine (CEO) purchased 50,000 shares at $7.12 per share price.Also, On Sep 1, 2015, Alaleh Nouri (SVP, General Counsel &) sold 957 shares at $6.80 per share price.
Accuray Incorporated is a radiation oncology company. The Company develops manufactures sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies the CyberKnife and TomoTherapy Systems are designed to deliver treatments including radiosurgery stereotactic body radiation therapy intensity modulated radiation therapy image guided radiation therapy and adaptive radiation therapy. Its principal radiosurgery products the CyberKnife Systems are robotic full-body radiosurgery system designed to treat tumors anywhere in the body non-invasively which include the CyberKnife M6 Series with configuration options of fixed collimators plus iris variable aperture collimator fixed collimators plus the InCise MLC and fixed collimators plus iris variable aperture collimator and the InCise MLC. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH TomoHD and TomoHDA.